MutationForecaster® (mutationforecaster.com) is Cytognomix’s patented web-portal for analysis of all types of mutations (coding and non-coding), including interpretation, comparison and management of genetic variant data. It’s a fully automated genome interpretation solution for research, translational and clinical labs.
MutationForecaster® combines our world-leading genome interpretation software on your exome, gene panel, or complete genome (Shannon transcription factor and splicing pipelines, ASSEDA, Veridical) with the Cytognomix User Variation Database and Variant Effect Predictor. With our integrated suite of software products, analyze coding, non-coding, and copy number variants, and compare new results with existing or your own database. Select predicted mutations by phenotype using articles with CytoVisualization Analytics. With Workflows, automatically perform end-to-end analysis with all of our software products.
Download an 1 page overview of MutationForecaster®: link .
You can now experience our integrated suite of genome interpretation products through a free trial of MutationForecaster®. Once you register, analyze datasets that we have analyzed in our peer-reviewed publications with any of our software tools.
Ionizing radiation produces characteristic chromosome changes. The altered chromosomes contain two central constrictions, termed centromeres, instead of one (known as dicentric chromosomes [DCs]). Chromosome biodosimetry is approved by the IAEA for occupational radiation exposure, radiation emergencies, or monitoring long term exposures. In emergency responses to a range of doses, labs need efficient methods that identify DCs.
Cytognomix has developed a novel approach to find DCs that is independent of chromosome length, shape and structure from different laboratories (paper: TBME). The Automated Dicentric Chromosome Identifier and Dose Estimator (ADCI) software works on multiple platforms and uses images produced by any of the existing automated metaphase capture systems found in most cytogenetic laboratories. ADCI is now available for for trial or purchase (link). Or contact us for details (pricing).
ADCI* uses machine learning based algorithms with high sensitivity and specificity that distinguish monocentric and dicentric chromosomes (Try the Dicentric Chromosome Identifier web app). With novel image segmentation, ADCI has become a fully functional cytogenetic biodosimetry system. ADCI takes images from all types of commercial metaphase scanning systems, selects high quality cells for analysis, identifies dicentric chromosomes (removing false positives), builds biodosimetry calibration curves, and estimates exposures. ADCI fulfills the criteria established by the IAEA for accurate triage biodosimetry of a sample in less than an hour. The accuracy is comparable to an experienced cytogeneticist. Check out our online user manual: wiki.
We find and validate mutations that others cannot with advanced, patented genomic probe and bioinformatic technologies. Cytognomix continues our long track record of creating technologies for genomic medicine. We anticipate and implement the needs of the biomedical and clinical genomics communities.
Browse the products section of the menu found in the header bar for more information regarding any of our services.
- Don’t want to run your own analyses on MutationForecaster®? Let us do it for you with our Bespoke Analysis Service.
- Customized genomic microarrays
- Ultrahigh resolution FISH probes:
- Microarray-based comparative genomic hybridization (aCGH) can use SC technology to increase reproducibility and reduce cost per sample.
The Atlas of Science has published a simplified description for the lay public of our 2016 study of gene variants in hereditary breast and ovarian cancer in BMC Medical Genomics (citation below). Please see: Focusing on the most relevant gene variants in inherited breast and ovarian cancer by Eliseos Mucaki and Peter Rogan. (http://atlasofscience.org/focusing-on-the-most-relevant-gene-variants-in-inherited-breast-and-ovarian-cancer/#more-16892) Original technical […]
Cytognomix has received a notice of allowance of all claims for US Pat. App. Ser. No. 13/744,459: Stable gene targets in breast cancer and use thereof for optimizing therapy Inventors: Peter K. Rogan and Joan H.M. Knoll The patent is based on our previous publication: Park et al. Structural and genic characterization of stable genomic regions […]
August 31, 2016. New publication on predicting outcomes of hormone and chemotherapy in breast cancer
Rezaeian I, Mucaki EJ, Baranova K et al. Predicting Outcomes of Hormone and Chemotherapy in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) Study by Biochemically-inspired Machine Learning. F1000Research 2016, 5:2124 (doi:10.12688/f1000research.9417.1) Paper URL: http://f1000research.com/articles/5-2124/v1
Dr. Peter K. Rogan presented “Reversing chromatin accessibility differences that distinguish homologous mitotic meetaphase chromosomes,”at the Gordon Research Conference on DNA Topoisomerases in Biology and Medicine at Sunday River in Newry, ME, United States.
MutationForecaster is catching on. Researchers, clinicians and commercial laboratories are realizing the value of being able to detect and interpret mutations that other platforms miss. Cytognomix has picked up multiple new subscribers from Germany, Switzerland, Australia, China, and Canada this year, and subscription renewals from last year. Cytognomix continues to push the envelope, for the […]
The paper can be accessed at: abstract or full text (web), or downloadable pdf . Please contact us if you would like a copy for non-commercial use.
Our previous preprint in bioRxiv on centromere detection has been published in F1000Research: Subasinghe A, Samarabandu J, Li Y et al. Centromere detection of human metaphase chromosome images using a candidate based method. F1000Research 2016, 5:1565 (doi:10.12688/f1000research.9075.1) URL Link.
Our paper, “Radiation Dose Estimation by Automated Cytogenetic Biodosimetry” by Peter K. Rogan, Yanxin Li, Ruth Wilkins, Farrah N. Flegal, and Joan H. M. Knoll, has been accepted for publication in the journal Radiation Protection Dosimetry. Figure 1. Representative processed metaphase image in ADCI: